{
    "ticker": "INAB",
    "name": "Inhibrx, Inc.",
    "description": "Inhibrx, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies to treat cancer and other serious diseases. Founded in 2014 and headquartered in La Jolla, California, Inhibrx leverages its proprietary protein engineering platform to create novel biologic therapies that target specific disease pathways. The company is known for its development of monoclonal antibodies and other protein-based therapeutics that aim to improve patient outcomes through precision medicine. Inhibrx has a robust pipeline, with multiple candidates in various stages of clinical development, including INBRX-109 and INBRX-105, which target different mechanisms of action in oncology. The company is committed to advancing its programs through rigorous clinical trials and collaborations with leading research institutions. With a mission to innovate and provide effective therapies for patients with unmet medical needs, Inhibrx is positioned to make significant contributions to the biopharmaceutical landscape.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "La Jolla, California, USA",
    "founded": "2014",
    "website": "https://www.inhibrx.com",
    "ceo": "Mark L. H. Hargreaves",
    "social_media": {
        "twitter": "https://twitter.com/Inhibrx",
        "linkedin": "https://www.linkedin.com/company/inhibrx/"
    },
    "investor_relations": "https://investors.inhibrx.com",
    "key_executives": [
        {
            "name": "Mark L. H. Hargreaves",
            "position": "CEO"
        },
        {
            "name": "Daniel L. H. Hargreaves",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology Therapies",
            "products": [
                "INBRX-109",
                "INBRX-105"
            ]
        }
    ],
    "seo": {
        "meta_title": "Inhibrx, Inc. | Innovative Biopharmaceuticals for Cancer Treatment",
        "meta_description": "Inhibrx, Inc. is dedicated to developing innovative therapies for cancer and other serious diseases. Explore Inhibrx's clinical pipeline and commitment to precision medicine.",
        "keywords": [
            "Inhibrx",
            "Biopharmaceuticals",
            "Cancer Treatment",
            "Monoclonal Antibodies",
            "INBRX-109",
            "INBRX-105"
        ]
    },
    "faq": [
        {
            "question": "What does Inhibrx focus on?",
            "answer": "Inhibrx focuses on developing innovative therapies for cancer and other serious diseases."
        },
        {
            "question": "Who is the CEO of Inhibrx?",
            "answer": "The CEO of Inhibrx is Mark L. H. Hargreaves."
        },
        {
            "question": "Where is Inhibrx headquartered?",
            "answer": "Inhibrx is headquartered in La Jolla, California, USA."
        },
        {
            "question": "What are Inhibrx's main products?",
            "answer": "Inhibrx's main products include INBRX-109 and INBRX-105, which are in clinical development for oncology."
        },
        {
            "question": "When was Inhibrx founded?",
            "answer": "Inhibrx was founded in 2014."
        }
    ],
    "competitors": [
        "MRNA",
        "BMY",
        "AMGN",
        "REGN"
    ],
    "related_stocks": [
        "GILD",
        "VRTX",
        "ALNY",
        "CRSP"
    ]
}